Unknown

Dataset Information

PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.


ABSTRACT: Sunitinib is used as standard treatment for metastatic or unresectable clear cell renal cell carcinoma (ccRCC). However, ccRCC eventually develops resistance to sunitinib in most cases, and the mechanisms underlying such resistance have not been fully determined. Nuclear receptors (NRs) are a class of transcription factors that regulate many cellular functions by controlling gene expression, and they also play important roles in tumor development, proliferation and progression in various types of cancers. In the present study, we aimed to explore the mechanisms underlying sunitinib resistance in RCC and the potential role of NRs in sunitinib resistance. The expression profile of NRs was obtained from the Gene Expression Omnibus (GEO) RNAseq database. A total of 138 patients from GSE65615 w

SUBMITTER: Aimudula A 

PROVIDER: S-EPMC6958248 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature